Skip to main content

Table 1 The clinical characteristics and treatment modalities of patients with NK/T-cell lymphoma

From: PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma

Parameters

Total n (%)

PD-L1 < 3.4 ng/ml n (%)

PD-L1 ≥ 3.4 ng/ml n (%)

P value

PD-L1 < 38 % n (%)

PD-L1 ≥ 38 % n (%)

P value

Overall

77 (100)

51 (100)

26 (100)

51 (100)

26 (100)

Male gender

42 (54.5)

23 (45.1)

19 (73.1)

0.020

26 (51.0)

16 (61.5)

0.379

Age > 60 years

11 (14.3)

10 (19.6)

1 (3.8)

0.087

9 (17.6)

2 (7.7)

0.316

ECOG score ≥ 2

4 (5.2)

1 (2.0)

3 (11.5)

0.109

2 (3.9)

2 (7.7)

0.600

Ann Arbor stage

 I

41 (53.2)

31 (60.8)

10 (38.5)

0.063

30 (58.8)

11 (42.3)

0.170

 II

36 (46.8)

20 (39.2)

16 (61.5)

 

21 (41.2)

15 (57.7)

 

B symptoms

22 (28.6)

12 (23.5)

10 (38.5)

0.170

13 (25.5)

9 (34.6)

0.433

LDH > 245 U/L

18 (23.4)

10 (19.6)

8 (30.8)

0.274

10 (19.6)

8 (30.8)

 

IPI score

 0–1

69 (89.6)

47 (92.2)

22 (84.6)

0.432

47 (92.2)

22 (84.6)

0.432

 2

8 (10.4)

4 (7.8)

4 (15.4)

 

4 (7.8)

4 (15.4)

 

NKPI score

 0–1

56 (72.7)

39 (76.5)

17 (65.4)

0.302

38 (74.5)

18 (69.2)

0.623

 2–3

21 (27.3)

12 (23.5)

9 (34.6)

 

13 (25.5)

8 (30.8)

 

Chemotherapy regimen

 GELOX

51 (66.2)

34 (66.7)

17 (65.4)

0.910

35 (68.6)

16 (61.5)

0.534

 CHOP-L

26 (33.8)

17 (33.3)

9 (34.6)

 

16 (31.4)

10 (38.5)

 

Treatment response

 CR

59 (76.6)

43 (84.3)

16 (61.5)

0.026

43 (84.3)

16 (61.5)

0.026

 Non-CR

18 (23.4)

8 (15.7)

10 (38.5)

 

8 (15.7)

10 (38.5)

 
  1. Abbreviations: CR complete remission, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index, LDH lactate dehydrogenase, NKPI natural killer/T-cell lymphoma prognostic index